MX2020013746A - Metodos y composiciones para incrementar la produccion de arn bicatenario. - Google Patents

Metodos y composiciones para incrementar la produccion de arn bicatenario.

Info

Publication number
MX2020013746A
MX2020013746A MX2020013746A MX2020013746A MX2020013746A MX 2020013746 A MX2020013746 A MX 2020013746A MX 2020013746 A MX2020013746 A MX 2020013746A MX 2020013746 A MX2020013746 A MX 2020013746A MX 2020013746 A MX2020013746 A MX 2020013746A
Authority
MX
Mexico
Prior art keywords
methods
compositions
double stranded
stranded rna
dsrna
Prior art date
Application number
MX2020013746A
Other languages
English (en)
Inventor
Juan Pedro Humberto Arhancet
John L Killmer
Patrick D Mclaughlin
Original Assignee
Apse Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apse Inc filed Critical Apse Inc
Publication of MX2020013746A publication Critical patent/MX2020013746A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se presentan métodos y materiales para la producción in vivo mejorada del ARNds. Los rendimientos del ARNds aumentan significativamente en presencia de la proteína de la cápside. El rendimiento mejorado del ARNds no depende de la presencia de sitios de unión afines específicos para la proteína de la cápside asociada con el ARNds, sino que depende de la proteína de la cápside.
MX2020013746A 2016-03-15 2018-09-14 Metodos y composiciones para incrementar la produccion de arn bicatenario. MX2020013746A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662308381P 2016-03-15 2016-03-15

Publications (1)

Publication Number Publication Date
MX2020013746A true MX2020013746A (es) 2021-03-02

Family

ID=59851196

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018011170A MX2018011170A (es) 2016-03-15 2017-03-09 Metodos y composiciones para incrementar la produccion de arn bicatenario.
MX2020013746A MX2020013746A (es) 2016-03-15 2018-09-14 Metodos y composiciones para incrementar la produccion de arn bicatenario.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018011170A MX2018011170A (es) 2016-03-15 2017-03-09 Metodos y composiciones para incrementar la produccion de arn bicatenario.

Country Status (11)

Country Link
US (3) US10704045B2 (es)
EP (1) EP3429336A4 (es)
JP (2) JP7140386B2 (es)
CN (2) CN109196102B (es)
AU (1) AU2017233862B2 (es)
BR (1) BR112018068144A2 (es)
CA (1) CA3016899C (es)
IL (1) IL261516A (es)
MX (2) MX2018011170A (es)
SG (1) SG11201807478QA (es)
WO (1) WO2017160600A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183022A1 (en) * 2015-05-12 2016-11-17 Apse, Llc In vivo production of long double stranded rna utilizing vlps
SG11201807478QA (en) 2016-03-15 2018-09-27 Apse Inc Methods and compositions for increased double stranded rna production
CN110494567B (zh) * 2017-03-28 2024-07-12 味之素株式会社 生产rna的方法
EP3976787A4 (en) * 2019-05-30 2023-10-25 Rnaissance AG L.L.C METHODS AND COMPOSITIONS FOR MICROBIAL ADMINISTRATION OF DOUBLE STRANDED RNA
WO2020243593A1 (en) 2019-05-30 2020-12-03 Apse, Inc. Improved methods and compositions for increased double stranded rna production

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164585A1 (en) 1998-01-16 2002-11-07 Sean Chapman Method for enhancing RNA or protein production using non-native 5' untranslated sequences in recombinant viral nucleic acids
US8772254B2 (en) 2004-10-25 2014-07-08 Devgen N.V. Method and constructs for delivering double stranded RNA to pest organisms
CA2608579C (en) * 2005-05-26 2019-09-10 Cytos Biotechnology Ag Scalable fermentation process
US8324149B2 (en) * 2008-11-18 2012-12-04 The Board Of Trustees Of The Leland Stanford Junior University Encapsidation of heterologous entities into virus-like particles
JP6041896B2 (ja) 2011-12-21 2016-12-14 アプス， エルエルシー 加水分解酵素に対して耐性があるカプシドを有するｖｌｐを用いるプロセス
GB201202119D0 (en) 2012-02-08 2012-03-21 Univ Swansea Pest and pathogen control
KR102271292B1 (ko) * 2013-03-15 2021-07-02 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집의 특이성을 증가시키기 위한 rna-안내 foki 뉴클레아제(rfn)의 용도
ES2691803T3 (es) 2013-03-15 2018-11-28 Monsanto Technology Llc Composiciones y procedimientos para la producción y administración de ARN
MX364809B (es) 2013-06-19 2019-05-07 Apse Llc Composiciones y metodos que se usan capsides resistentes a hidrolasas.
WO2015038746A1 (en) * 2013-09-11 2015-03-19 Georgia Tech Research Corporation Compositions and methods for inhibiting gene expression
US10329560B2 (en) 2013-09-23 2019-06-25 Georgia Tech Research Corporation Targeting non-coding RNA for RNA interference
WO2015073720A1 (en) 2013-11-14 2015-05-21 Scarab Genomics, Llc Bacteria with improved metabolic capacity
WO2016183022A1 (en) 2015-05-12 2016-11-17 Apse, Llc In vivo production of long double stranded rna utilizing vlps
SG11201807478QA (en) 2016-03-15 2018-09-27 Apse Inc Methods and compositions for increased double stranded rna production

Also Published As

Publication number Publication date
AU2017233862B2 (en) 2023-04-13
WO2017160600A1 (en) 2017-09-21
SG11201807478QA (en) 2018-09-27
CN109196102A (zh) 2019-01-11
AU2017233862A1 (en) 2018-10-04
CA3016899C (en) 2023-09-19
MX2018011170A (es) 2019-05-16
CA3016899A1 (en) 2017-09-21
US20190093108A1 (en) 2019-03-28
IL261516A (en) 2018-10-31
JP2019508060A (ja) 2019-03-28
US20230416744A1 (en) 2023-12-28
JP7544761B2 (ja) 2024-09-03
CN109196102B (zh) 2022-04-26
EP3429336A1 (en) 2019-01-23
US11718851B2 (en) 2023-08-08
US20220145294A1 (en) 2022-05-12
US10704045B2 (en) 2020-07-07
BR112018068144A2 (pt) 2019-02-12
CN115927299A (zh) 2023-04-07
JP2022087312A (ja) 2022-06-09
JP7140386B2 (ja) 2022-09-21
EP3429336A4 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
MX2020013746A (es) Metodos y composiciones para incrementar la produccion de arn bicatenario.
PH12019502283A1 (en) Anti-lag3 antibodies
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2024004646A (es) Proteinas de union de cadena unica de fragmento variable cd3.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2019006043A (es) Proteína de unión de antígeno prostático específico de membrana.
MX2019002946A (es) Anticuerpos anti-pd-1 y sus usos.
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
WO2014172046A3 (en) Gene fusions and gene variants associated with cancer
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
MX2017009937A (es) Cepas fungicas y metodos de uso.
MX2016016886A (es) Anticuerpos anti-axl.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
MX2016012371A (es) Anticuerpos multiespecificos.
MY185817A (en) Methods for production of oxygenated terpenes
MX2016003944A (es) Composiciones y formulaciones para mantener y aumentar la masa muscular, fuerza y rendimiento y metodos de produccion y usos de los mismos.
GB2547587A (en) Transgenic mice
WO2015149034A3 (en) Gene fusions and gene variants associated with cancer
MX2017007941A (es) Anticuerpos antagonistas anti-axl.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
TW201613893A (en) Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
MY172601A (en) Improved process for preparing fermented soybean meal
MY182924A (en) Enzyme compositions and uses thereof
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.